Hemispherx Expands Its Manufacturing Facilities

Hemispherx Expands Its Manufacturing Facilities post image

We also received positive news from our biotech stock Hemispherx Biopharma (HEB – $2.05). The Company will spend up to $4.4 million for engineering studies, capital improvements, system upgrades, and introduction of building management systems to enhance production for Alferon N and its two experimental therapeutics Alferon LDO and Ampligen.

These investments will bring the capacity of Hemispherx’ manufacturing site in New Brunswick in alignment with the projected commercial supply forecast for both Alferon LDO and Ampligen indications to serve markets for up to three years post approval.

Is this good news? We believe so. We feel it means HEB is pushing aggressively to move the clinical trials forward and secondly it means, if anything, the company hasn’t heard to many negative comments from the FDA about the potential approval for Ampligen. And yes, Dr. Carter said on the Rodman conference he hadn’t been in contact with the FDA for quite some time, but that doesn’t mean other people like Dr. Strayer, HEB’s medical director, haven’t been in contact with the agency.

This is why we supported HEB’s public offerings a few months ago, as the Company now has the money to spend on critical items.

0 comments… add one

Leave a Comment